Bayer Bets On Oncology Pipeline, Vows To Increase 2017 R&D Budget

Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

Bayer Board — Bayer Execs In Leverkusen (L-R): Johannes Dietsch, Werner Baumann, Hartmut Klusik and Michael Preuss • Source: Scrip/ Lucie Ellis

Bayer AG invested around 13% of the group's 2016 sales, or €4.4bn, in research. During the company's Feb. 22 annual results presentation in Leverkusen, Germany, CEO Werner Baumann called innovation the company's core competence – and as such the drug maker has launched a new internal oncology R&D arm, with more autonomy, to speed up decision making and R&D for its pipeline cancer therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

05 May 2025

• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.